Arca
Skip to content
Tools
Tools

Frontotemporal dementia

Drug research and approvals for frontotemporal dementia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 96 studies of frontotemporal dementia are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 0 approved and 11 open orphan designations naming it.

  • Recruiting worldwide: 96
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 96 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 2

Phase 2 6

Phase 1 or earlier 3

How its trials ended

260 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 39 whose ending is known, 28% met their primary endpoint, 5% missed it and 67% stopped early.

  • Ongoing10540%
  • Completed, result not reported9938%
  • Status unknown177%
  • Stopped: other or unclear166%
  • Met its primary endpoint114%
  • Stopped: sponsor or business decision42%
  • Stopped: lack of efficacy31%
  • Missed its primary endpoint21%
  • Stopped: enrollment or feasibility21%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 13, 2023A multicenter, open-label extension (OLE) study to evaluate the safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9ORF72-associated…WVE-004Wave Life Sciences Uk LtdClosed
Sep 27, 2022Double blind crossover trial of nabilone for agitation in frontotemporal dementia (nabilone-ftd)NabiloneDouglas Mental Health University InstituteClosed
Apr 16, 2021A phase 1bopen-label, multicenter, dose escalationstudy to assessthe safety, tolerability and pharmacodynamic effects of a single dose of PBFT02DELIVERED into…PBFT02 / Methylprednisolone / PrednisonePassage BIOOngoing
Jan 15, 2021A multicenter, randomized, double-blind, placebo-controlled, phase 1b/2a study of WVE-004 administered intrathecally to patients with C9ORF72-associated…WVE-004Wave Life Sciences Uk LtdClosed
Jun 21, 2019A phase 2, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of…AL001AlectorClosed
Feb 13, 2019"a first in human phase 1 study in healthy volunteers and heterozygous carriers of a loss-of-function granulin mutation causative of frontotemporal dementia to…AL001 {recombinant anti-human sortilin (SORT1) monoclonal igg G1M17,1 [or G1M…AlectorPending
Apr 28, 2017A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementiaOxytocinDr Elizabeth FingerOngoing
Aug 6, 2014An open-label, extension study of the effects of leuco-methylthioninium bis(hydromethanesulfonate) in subjects with Alzheimer's disease or behavioral variant…Leuco-methylthioninium bis(hydromethanesulfonate) (lmtm, TRX0237)Taurx Therapeutics LtdClosed
Aug 26, 2013The impact of emotional mimicry and oxytocin on ftdOxytocinDr Elizabeth FingerOngoing
May 10, 2013A double-blind, placebo-controlled, randomized, parallel group, 12-month safety and efficacy trial of leuco-methylthioninium bis(hydromethanesulfonate) in…Leuco-methylthioninium bis(hydromethanesulfonate) (lmtm, TRX0237)Taurx Therapeutics LtdClosed

FDA orphan designations

Approved first, then open designations, newest first
Aug 3, 2026Progranulin replacement therapyTreatment of frontotemporal dementiaDenali Therapeutics Inc.Designated
Nov 25, 2024NeflamapimodTreatment of frontotemporal dementiaEIP Pharma, LLCDesignated
Mar 7, 2023RifampinTreatment of Frontotemporal DementiaMedilabo RFP, Inc.Designated
Nov 24, 2021Recombinant AAV9 vector encoding the human progranulin…Treatment of frontotemporal dementia (FTD)AviadoBio Ltd.Designated
Jan 7, 2021Non-replicating recombinant adeno-associated virus serotype…Treatment of frontotemporal dementiaPassage Bio, Inc.Designated
Sep 9, 2020FasudilTreatment of Frontotemporal DementiaWoolsey Pharmaceuticals, Inc.Designated
Dec 5, 2019Non-replicating recombinant adeno-associated virus serotype…Treatment of frontotemporal dementiaPrevail TherapeuticsDesignated
Nov 20, 2018Hydromethylthionine mesylateTreatment of frontotemporal dementiaTau Rx Therapeutics Management Ltd.Designated
Nov 21, 2016Isoindolin-1,3-Di ThioneTreatment of Frontotemporal dementiaP2D, Inc.Designated
Jul 13, 2016Tolfenamic acidTreatment of Frontotemporal DementiaNasser H. ZawiaDesignated
Apr 6, 20161-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-in…Treatment of frontotemporal dementia.Anavex Life Sciences Corp.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.